Therapeutic outcomes of combined Bupivacaine Liposome, 1,4-Butanediol Diglycidyl Ether-crosslinked sodium hyaluronate, and arthroscopic debridement in knee osteoarthritis management.

Objective: To assess the effectiveness of arthroscopic debridement (AD) combined with Bupivacaine Liposome and 1,4-Butanediol Diglycidyl Ether (BDDE)-Crosslinked Sodium Hyaluronate in treating knee osteoarthritis (KOA).

Methods: A total of 195 KOA patients were recruited and assigned to two groups based on the treatment modality: a control group (n=95) receiving standard AD and a research group (n=100) receiving the combined therapy. The efficacy of the treatment, inflammatory biomarkers (including tumor necrosis factor-alpha [TNF-α], interleukin [IL]-1β, and IL-6), quality of life (QOL), and patient-reported satisfaction were assessed. Besides, multiple scales were employed, including the Visual Analog Scale (VAS) for pain intensity, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for symptom severity, as well as the Hospital for Special Surgery (HSS) Knee Score and Lysholm Knee Score for functional recovery.

Results: The research group demonstrated significantly superior overall efficacy and treatment satisfaction compared to the control group (P<0.05). Post-intervention improvements were observed in knee function scores (HSS and Lysholm) and QOL in both cohorts, with the research group showing greater enhancements (P<0.05). Furthermore, the combination therapy led to more pronounced reductions in WOMAC subscale scores (dysfunction, pain, and stiffness), VAS scores, and inflammatory markers (TNF-α, IL-1β, and IL-6) compared to the control group (P<0.05).

Conclusions: The combination of Bupivacaine Liposome, BDDE-Crosslinked Sodium Hyaluronate, and AD shows great therapeutic potential in the management of KOA, supporting its broad clinical generalization.